Given the price action in QGENF over the last three days to the present, the Robbie Stevens downgrade today is most interesting. QGENF got whacked on no news for the prior two days, but is up on a tough morning today -- the morning the downgrade was publicly issued. Obviously, this does little to endear me to Robbie Stevens, as someone who is not a big client of theirs. Sheesh.
But Trickle's buy at $16.10 is looking OK so far, so maybe I should thank them for the opportunity, if grudgingly.
Meanwhile, BCOR reports, and it isn't good. Almost sold this a few days ago to raise more cash. 20/20 hindsight.
>>UPPSALA, Sweden, Feb. 21, 2002 (PRIMEZONE via COMTEX) -- Biacore (Nasdaq: BCOR chart, msgs):
-- Biacore's sales in the fourth quarter of 2001 increased by 6% to
SEK 175.0 million (165.3). For the full-year 2001, sales increased
by 24% to SEK 543.7 million (438.8).
-- Biacore continued its strategy of investing in developing its
successful business with the pharmaceutical and biotechnology
industries, as well as the commercialization of its unique SPR
array chip technology. As a result of these investments and a
one-off pension cost in the fourth quarter, full year earnings
per share fell by 16% to SEK 5.04 (6.02). Earnings per share in
the last quarter fell to SEK 1.68 (2.80). Excluding the one-off
cost, earnings per share amounted to SEK 6.32 for the full-year
and SEK 2.97 in the last quarter 2001.
-- Biacore(r)S51, the Company's first new high-performance system
for lead optimization and certain specific ADME applications, has
been well accepted by the market with sales made to a number of
companies including Millennium and Roche.
-- Biacore signed an important collaboration with Bruker Daltonics
Inc., which is designed to commercialize the combination of SPR
and mass spectrometry for functional proteomics applications.
-- Dr. Ulf Jonsson was appointed Chief Executive Officer of Biacore
International AB effective January 1, 2002. As of the same date,
Lars- Goran Andren, Biacore's previous Executive Chairman and
CEO, became the Company's Non-Executive Chairman.
-- Biacore is confident about its future growth prospects and
expects its sales to increase by approximately 20% in 2002, with
substantial quarterly variations. After substantial investments
during 2001, combined marketing and administration costs are
expected to increase by no more than 10% in 2002. In addition to
the Company's on-going level of R&D spending, which is targeted
at 15% of sales, Biacore plans to invest in the region of SEK 35
million in 2002 on commercializing its SPR array chip technology.
January - December October - December
2001 2000 Change 2001 2000 Change
Sales, SEK million 543.7 438.8 +24% 175.0 165.3 +6%
Operating income,
SEK million 64.1 78.0 -18% 25.7 37.6 -32%
Operating margin, % 12 18 15 23
Income after financial
items, SEK million 77.9 86.7 -10% 27.7 40.6 -32%
Diluted earnings
per share, SEK 5.04 6.02 -16% 1.68 2.80 -40%
This information was brought to you by Waymaker waymaker.net
The following files are available for download:
www.waymaker.net/bitonline/2002/02/21/20020221BIT00100/bit0002.doc
The Full Year-End Report
www.waymaker.net/bitonline/2002/02/21/20020221BIT00100/bit0002.pdf
The Full Year-End Report<<
Cheers, Tuck |
